Oruka Therapeutics is a clinical-stage biopharmaceutical company developing novel monoclonal antibody therapeutics targeting the IL-23 and IL-17 pathways for psoriasis, hidradenitis suppurativa, psoriatic arthritis, and other inflammatory and immunology indications. The company applies antibody engineering and half-life extension technology to validated mechanisms of action, aiming to deliver improved efficacy, safety, and dosing convenience compared to existing standard-of-care medicines while reducing development risk. Oruka's lead programs include ORKA-001 targeting IL-23p19 and ORKA-002 targeting IL-17A/F, both designed to enable reduced-frequency subcutaneous or intravenous dosing; the company intends to commercialize approved products through independent or partnership-based approaches once regulatory approval is achieved.